Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KTN3379 in resectable head and neck cancer
NCT02473731Phase 1Completed
- Sponsor
- Celldex Therapeutics
- Start
- Oct 2015
- Primary completion
- Sep 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of cdx-3379 in squamous cell carcinoma of the head and neck (HNSCC) (2 arms), sponsored by Celldex Therapeutics. Primary endpoint: Change in pErbB3 levels in tumor tissue at 4 weeks. Started Oct 2015; status: completed.
02
Drugs
cdx-3379
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02473731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02473731.